SBIR/STTR Research Award
Combinatorial Macrolide GPCR Screening Library
Award amount
$105,000Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Kosan Biosciences, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): The long-term objective of this proposal
is to identify and develop new drugs by identifying novel ligands for G
protein-coupled receptors (GPCRs). GPCRs have been shown to be the molecular
target of many marketed drugs. Several macrolide structures have been shown to
act as agonists or antagonists against GPCRs, so a combinatorial library of
macrolide structures screened against a battery of orphan GPCRs would likely
yield an array of agonists and antagonists. These macrolide ligands could then
be used to elucidate the biology of the orphan receptors, and would likely lead
to the development and commercialization of new drugs. This proposal is thus
directed towards the synthesis of a library of macrolides using high-speed
parallel synthesis. During Phase I, the chemistry to produce the first two
subsets of compounds will be developed, and analogs generated will be screened
for activity against the motilin receptor as a proof-of-concept. Phase II will
be directed to development of the remaining chemistry and the synthesis of the
remaining library members. The library will be expanded to ca. 1000
members, and will be screened in collaboration with Glaxo SmithKline.
PROPOSED COMMERCIAL APPLICATIONS:
Agonists of the Motilin receptor could be used in the attachment of gastroesophageal
reflux disease and gastroparesis. Both diseases have significant markets, and
development of suitable treatments would have substantial commercial prospects. The
discovery of agonist or antagonist ligands for orphan GPCRs would aid in the
characterization of novel targets for new drugs.
Technology keywords
Not reported